← feed

Is NCT03156361 results overdue?

Yes — results are overdue. Primary completion was 2018-01-15; the FDAAA-801 reporting deadline (2019-01-15) passed 2714 days ago and no results are posted on ClinicalTrials.gov.

21 Day Comparison of Continuous Insulin Infusion Using HDV Insulin to Standard Insulin in Type 1 Diabetes Mellitus

NCT IDNCT03156361 ↗
SponsorDiasome Pharmaceuticals (INDUSTRY)
PhasePHASE2
StatusCOMPLETED
Primary completion2018-01-15 (ACTUAL)
Reporting deadline2019-01-15 (completion + 365d)
Days overdue2714
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 c9665aa8d015fdd2… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03156361. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →